• 2018 clinical trial for PKU candidate boosts pipeline for Nestlé Health Science’s Vitaflo business


• Partnership to leverage Codexis’ enzyme discovery platform to fuel therapeutic and nutritional innovation

 

Epalinges, Switzerland, 12 October 2017 – As part of its core strategy to advance the therapeutic role of nutrition, Nestlé Health Science (NHSc) is forming an innovation partnership with Codexis (NASDAQ: CDXS), a pioneer in protein engineering and enzyme optimization. The partnership will leverage and extend the application of Codexis’ CodeEvolver^® protein engineering platform, creating novel enzymes that will further fuel innovation for NHSc’s subsidiary Vitaflo, specializing for inborn errors of metabolism, as well as for NHSc’s Consumer Care and Medical Nutrition portfolio.

Full press release